← All trials
NCT05698550
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Jan 26, 2023
- Last posted
- Oct 31, 2023
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong University of Traditional Chinese MedicineLead sponsor
- Chongqing Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Shandong University of Traditional Chinese MedicineReponsible party - principal investigator
- Shanxi Medical UniversityCollaborator
- Shandong University of Traditional Chinese MedicineSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.